Last $1.84 USD
Change Today -0.02 / -1.08%
Volume 582.1K
CRIS On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - $3.40
52 Week Low
12/18/14 - $1.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

33 Employees
Last Reported Date: 03/13/14
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis, Inc. - Special Call

To discuss exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets

Curis, Inc. and Aurigene Discovery Technologies Limited Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

Curis, Inc. and Aurigene Discovery Technologies Limited announced that they have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The partnership draws from each company's respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and preclinical activities, including IND-enabling studies and providing Phase 1 clinical trial supply, and Curis having responsibility for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia, for each program for which it exercises an option to obtain a license. The first two programs under the collaboration are an orally-available small molecule antagonist of programmed death ligand-1 (PD-L1) in the immuno-oncology field and an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field. Curis expects to exercise its option to obtain exclusive licenses to both programs and file IND applications for a development candidate from each in 2015. The agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Curis to extend the broad immuno-oncology exclusivity. Curis has agreed to pay Aurigene royalties on any net sales ranging from high single digits to 10% in territories where it successfully commercializes products and will also share in amounts that it receives from sublicensees depending upon the stage of development of the respective molecule.

Curis, Inc.(NasdaqGM:CRIS) dropped from NASDAQ Biotechnology Index

Curis, Inc. will be removed from the NASDAQ Biotechnology Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $1.84 USD -0.02

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.16 USD +0.01
Delcath Systems Inc $1.24 USD -0.03
Exelixis Inc $1.87 USD -0.10
MELA Sciences Inc $1.38 USD -0.01
Navidea Biopharmaceuticals Inc $1.61 USD -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.9x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at